Positive Phase 1b Results for I-Mab's Givastomig in Metastatic Gastric Cancer Show 71% Objective Response Rate with Favorable Safety Profile
26/6 12:40
I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile....